Amgen Announces Initiation of Phase 3 Trial to Evaluate the Impact of Treating Anemia with Darbepoetin Alfa
Amgen announced that it will initiate a Phase 3 randomized, placebo-controlled, double-blind, multicenter, multi-national trial to evaluate the effect of anemia treatment with darbepoetin alfa on morbidity and mortality in patients with heart failure.
"Amgen's decision to proceed with its Phase 3 trial in heart failure is driven both by results from epidemiological studies, as well as by our recently completed Phase 2 pilot studies of anemia treatment in heart failure patients which provided us with encouraging results," said Willard Dere, M.D., senior vice president for Global Development and chief medical officer at Amgen. "We are excited at the potential for darbepoetin alfa to help heart failure patients, especially given the grievous nature of this illness. Despite the use of various currently available treatment options, the morbidity and mortality associated with heart failure remains high, and we hope that darbepoetin alfa will help address this important unmet medical need."
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
VTT printed haemoglobin test on paper: Bioactivity presents new opportunities for paper
GENE-TRAK Listeria Microwell Test Receives AOAC Validation
MorphoSys Announces Clinical Milestone in Therapeutic Antibody Program - Seventh HuCAL Antibody to Enter Clinical Trials

Malaria pathogens under the X-ray microscope - X-ray microscopy at BESSY II reveals how antimalaria-drugs might work

New app calculates corona infection risk in rooms - Size of aerosol droplets that virus carriers release strongly influences infectivity
